Loading...
XTAI1734
Market cap169mUSD
Dec 26, Last price  
30.55TWD
1D
3.91%
1Q
-7.00%
Jan 2017
36.63%
Name

Sinphar Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XTAI:1734 chart
P/E
14.75
P/S
1.87
EPS
2.07
Div Yield, %
3.03%
Shrs. gr., 5y
1.58%
Rev. gr., 5y
5.98%
Revenues
2.96b
+3.72%
1,813,468,0001,822,648,0001,840,266,0002,086,627,0002,577,907,0002,642,145,0002,187,401,0002,133,511,0002,134,163,0002,215,837,0002,394,589,0002,388,452,0002,433,516,0002,856,651,0002,962,934,000
Net income
375m
+128.52%
131,034,000110,930,00072,229,000121,304,000300,691,000163,393,00013,952,00016,545,00036,726,0008,785,000-147,922,000-172,559,000-204,959,000164,174,000375,170,000
CFO
296m
-30.31%
309,944,000261,494,000225,583,000164,449,000297,092,000148,580,000280,533,00087,184,000219,871,00079,502,000-79,486,000146,392,000135,544,000425,298,000296,370,000
Dividend
Sep 04, 20241 TWD/sh
Earnings
Jun 19, 2025

Profile

Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, researches, develops, manufactures, and sells therapeutic drugs, health care foods, and medical beauty products in Taiwan and internationally. It produces anti-cancer pharmaceuticals, such as injections, solid reagents, and hormone reagents; and tablets, soft gel capsules and powder and canned special nutrient products. The company also offers shampoo, body wash, tonic water, lotions, moisturizers, sunscreen lotions, and serums; and pharmaceutical packaging products, such as eye drop bottles, dry canisters, tablet bottles, and various medical grade plastic containers. In addition, it provides plant extracts and functional foods; and OEM services, such as product design, manufacturing, etc. to manufacturers. The company was founded in 1977 and is headquartered in Yilan City, Taiwan.
URL
http://www.sinphar.com/
IPO date
Oct 17, 2000
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,962,934
3.72%
2,856,651
17.39%
2,433,516
1.89%
Cost of revenue
2,672,515
2,658,849
2,613,750
Unusual Expense (Income)
NOPBT
290,419
197,802
(180,234)
NOPBT Margin
9.80%
6.92%
Operating Taxes
(51,068)
80,872
20,434
Tax Rate
40.89%
NOPAT
341,487
116,930
(200,668)
Net income
375,170
128.52%
164,174
-180.10%
(204,959)
18.78%
Dividends
(167,722)
(33,544)
(33,544)
Dividend yield
2.94%
0.65%
0.75%
Proceeds from repurchase of equity
30,043
100,580
BB yield
-0.53%
-2.24%
Debt
Debt current
450,878
497,899
648,446
Long-term debt
1,494,142
1,415,618
1,485,954
Deferred revenue
Other long-term liabilities
154,371
106,814
123,295
Net debt
841,659
651,266
919,256
Cash flow
Cash from operating activities
296,370
425,298
135,544
CAPEX
(295,510)
(153,445)
(161,444)
Cash from investing activities
(334,563)
(124,238)
(205,597)
Cash from financing activities
(106,842)
(263,325)
122,953
FCF
38,163
145,606
(164,348)
Balance
Cash
1,081,149
1,244,216
1,244,885
Long term investments
22,212
18,035
(29,741)
Excess cash
955,214
1,119,418
1,093,468
Stockholders' equity
2,975,424
2,478,127
2,304,918
Invested Capital
4,542,051
4,072,354
4,206,137
ROIC
7.93%
2.82%
ROCE
5.28%
3.81%
EV
Common stock shares outstanding
181,473
168,013
167,722
Price
31.44
2.44%
30.69
14.69%
26.76
-6.63%
Market cap
5,705,526
10.65%
5,156,319
14.89%
4,488,241
-6.63%
EV
6,846,721
6,094,203
5,762,441
EBITDA
533,943
464,516
89,136
EV/EBITDA
12.82
13.12
64.65
Interest
33,711
27,813
24,799
Interest/NOPBT
11.61%
14.06%